Roger
Jeffs,
Ph.D.
Chief Executive Officer
Roger Jeffs, Ph.D. joined Liquidia as its CEO in 2022 after serving on the company’s Board of Directors beginning in 2020. In addition, Roger is the Vice-Chairman and Co-Founder of Kryia Therapeutics, a company focused on accelerating the development of innovative gene therapy programs for both rare and prevalent diseases. He currently serves on the Boards of Liquidia (LQDA) and Axsome Therapeutics (AXSM), and previously served on the Board of Directors of United Therapeutics (UTHR) from 2001-2016, Dova Pharmaceuticals (DOVA) from 2017-2019, Sangamo Therapeutics (SGMO) from 2017-2019, Axovant Gene Therapies (AXGT) from 2017-2019, and Albireo Pharma (ALBO) from 2017-2021.
Roger retired as President & Co-CEO of United Therapeutics Corporation in 2016 after an 18-year tenure. He joined United Therapeutics during its start-up phase in 1998 as director of research, development and medical, and served as its President and Chief Operating Officer from 2001 to 2014, and President & Co-CEO from 2015-2016. While at United Therapeutics, Roger helped lead its IPO, oversaw the clinical development and regulatory approval of six products for rare diseases, and managed the commercial effort that led to a >20% CAGR, a $1.5B annual revenue run rate and a $8B peak market cap. During his tenure, United Therapeutics was consistently recognized as one of the fastest growing companies and best places to work. Previous to his roles at United Therapeutics, Roger held positions in clinical development at Amgen, Inc. and Burroughs Wellcome Co.
In 2015, Roger received the 2015 Wings of Hope Award from the Solving Kids’ Cancer organization in "recognition of his visionary leadership in advancing cancer research while prioritizing the lives of children." He holds an undergraduate degree in chemistry from Duke University and a Ph.D. in pharmacology from the University of North Carolina School of Medicine.
Roger Jeffs, Ph.D. joined Liquidia as its CEO in 2022 after serving on the company’s Board of Directors beginning in 2020. In addition, Roger is the Vice-Chairman and Co-Founder of Kryia Therapeutics, a company focused on accelerating the development of innovative gene therapy programs for both rare and prevalent diseases. He currently serves on the Boards of Liquidia (LQDA) and Axsome Therapeutics (AXSM), and previously served on the Board of Directors of United Therapeutics (UTHR) from 2001-2016, Dova Pharmaceuticals (DOVA) from 2017-2019, Sangamo Therapeutics (SGMO) from 2017-2019, Axovant Gene Therapies (AXGT) from 2017-2019, and Albireo Pharma (ALBO) from 2017-2021.
Roger retired as President & Co-CEO of United Therapeutics Corporation in 2016 after an 18-year tenure. He joined United Therapeutics during its start-up phase in 1998 as director of research, development and medical, and served as its President and Chief Operating Officer from 2001 to 2014, and President & Co-CEO from 2015-2016. While at United Therapeutics, Roger helped lead its IPO, oversaw the clinical development and regulatory approval of six products for rare diseases, and managed the commercial effort that led to a >20% CAGR, a $1.5B annual revenue run rate and a $8B peak market cap. During his tenure, United Therapeutics was consistently recognized as one of the fastest growing companies and best places to work. Previous to his roles at United Therapeutics, Roger held positions in clinical development at Amgen, Inc. and Burroughs Wellcome Co.
In 2015, Roger received the 2015 Wings of Hope Award from the Solving Kids’ Cancer organization in "recognition of his visionary leadership in advancing cancer research while prioritizing the lives of children." He holds an undergraduate degree in chemistry from Duke University and a Ph.D. in pharmacology from the University of North Carolina School of Medicine.